2026paź
EW Oct 2026 · Sell
Edwards Lifesciences Corporation carries a Sell rating with a synthesized fair value midpoint of $62.28 per share against a market price of $85.71 as of October 2, 2026, representing an implied downside of -27.33% and a 37.61% premium to fair value. Despite an elite wide moat in structural heart therapies evidenced by 78.01% gross margins, forward market pricing at 25.64x forward P/E is disconnected from peer multiples (BSX at 12.55x, SYK at 16.48x) while procedural expansion faces domestic hospital cath lab staffing and capacity constraints.Latest published research · analyzed 2026-10-02 · current · sources aging